219 completed, 74 unknown, 54 terminated, 49 recruiting. 457 Phase 3, 76 Phase 2.
Follow Leukemia, Myeloid: new trials by email Literature Review of Leukemia, Myeloid trials Research Report on Leukemia, Myeloid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Not yet recruiting | Enliven Therapeutics | 450 | 2026-12-31 | 2026-10-29 |
| FLT3-ITD Targeted Therapy in Fit AML Patients Gilteritinib, Venetoclax, Azacitidine (AZA) - AML (Acute Myeloid Leukemia) | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 230 | 2026-12-01 | 2026-02-23 |
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy IPN60340 + azacitidine + venetoclax, Placebo + azacitidine + venetoclax - Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia | Phase 2 / Phase 3 | Not yet recruiting | Ipsen | 540 | 2026-11-01 | 2026-09-10 |
| Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML Unrelated Umbilical Cord Blood Infusion, Standard consolidation chemotherapy with high-dose cytarabine - AML (Acute Myelogenous Leukemia) | Phase 3 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 132 | 2026-10-01 | 2026-08-12 |
| Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia Best Practice, Biospecimen Collection, Cytarabine - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 556 | 2026-08-14 | 2026-09-04 |
| Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse Lisaftoclax Plus Azacitidine - Acute Myeloid Leukemia (AML), Maintenance Treatment | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 191 | 2026-08-10 | 2026-07-07 |
| Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML Mitoxantrone Hydrochloride Liposome, Cytarabine, Granulocyte Colony-Stimulating Factor(G-CSF) - Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | Phase 3 | Not yet recruiting | Ruijin Hospital | 168 | 2026-07-30 | 2026-07-29 |
| Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) Azacitidine, Venetoclax, Quizartinib - Acute Myeloid Leukemia, Adult | Phase 3 | Recruiting | PETHEMA Foundation | 376 | 2026-07-02 | 2026-11-04 |
| Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients Lisaftoclax (APG-2575) - Acute Promyelocytic Leukemia (APL) | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 20 | 2026-07-01 | 2026-06-30 |
| A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Pivekimab Sunirine, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | AbbVie | 660 | 2026-06-30 | 2026-10-22 |
| Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Recruiting | Quetzal Therapeutics | 150 | 2026-06-08 | 2026-10-30 |
| VABu Conditioning in Elderly AML HSCT VaBU - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Acute Myeloid Leukemia (AML) | Phase 2 / Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 20 | 2026-05-07 | 2026-05-14 |
| MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib Gilteritinib, Sorafenib - Acute Myeloid Leukemia (AML), FLT3-ITD Mutation | Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 594 | 2026-05-01 | 2026-03-20 |
| VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML Gilteritinib + Azacitidine + Venetoclax, Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib, Re-induction Therapy - AML, Adult | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 300 | 2026-04-30 | 2026-03-25 |
| VAH vs VA in Newly Diagnosed Elderly AML Venetoclax, Azacitidine, Homoharringtonine - Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years) | Phase 3 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 308 | 2026-04-10 | 2026-04-13 |
| A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia BL-M11D1, Cytarabine, Daunorubicin - Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 216 | 2026-04-02 | 2026-09-10 |
| VEN+IDAC vs IDAC in AML Ventoclax, Cytarabine - AML (Acute Myelogenous Leukemia) | Phase 2 / Phase 3 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 232 | 2026-04-01 | 2026-04-17 |
| TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients TGRX-678, TKI - Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase | Phase 3 | Not yet recruiting | Shenzhen TargetRx Co., Ltd. | 180 | 2026-04-01 | 2026-03-24 |
| DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML Arm A (VEN+"2+6"DA), Arm B (DEC3-VEN), Arm C ("3+7"DA) - AML (Acute Myeloid Leukemia) | Phase 3 | Recruiting | The Second Affiliated Hospital of Kunming Medical University | 291 | 2026-04-01 | 2026-07-20 |
Showing 20 of 457. Sign in to see all of them.
Leukemia, Myeloid, Acute (329) · Leukemia (111) · Myelodysplastic Syndromes (91) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (85) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (77) · Leukemia, Myeloid, Chronic-Phase (58) · Leukemia, Myelomonocytic, Chronic (45) · Lymphoma, Non-Hodgkin (38) · Myeloproliferative Disorders (36) · Leukemia, Lymphocytic, Chronic, B-Cell (35) · Lymphoma (35) · Hodgkin Disease (32) · Leukemia, Myeloid, Accelerated Phase (32) · Burkitt Lymphoma (30) · Congenital Abnormalities (30)
Hemic and Lymphatic Diseases (457) · Neoplasms by Histologic Type (454) · Hematologic Diseases (449) · Neoplasms (437) · Leukemia (346) · Bone Marrow Diseases (207) · Pathological Conditions, Signs and Symptoms (177) · Pathologic Processes (175) · Disease Attributes (167) · Chronic Disease (157) · Myeloproliferative Disorders (123) · Immune System Diseases (94) · Immunoproliferative Disorders (87) · Lymphatic Diseases (87)
Cytarabine (125) · Azacitidine (60) · Daunorubicin (58) · Idarubicin (42) · venetoclax (41) · Cyclophosphamide (39) · Etoposide (36) · Imatinib Mesylate (34) · Busulfan (32) · Decitabine (29) · Methotrexate (29) · fludarabine (29) · Mitoxantrone (27) · nilotinib (26) · Gemtuzumab (20)
Novartis Pharmaceuticals (22) · The First Affiliated Hospital of Soochow University (17) · European Organisation for Research and Treatment of Cancer - EORTC (15) · Children's Oncology Group (11) · Nanfang Hospital, Southern Medical University (10) · National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (9) · University of Ulm (9) · AbbVie (8) · Fred Hutchinson Cancer Center (8) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (7) · Stichting Hemato-Oncologie voor Volwassenen Nederland (6) · Acute Leukemia French Association (5) · Astex Pharmaceuticals, Inc. (5) · Bristol-Myers Squibb (5)
United States (186) · Germany (126) · France (115) · Italy (96) · China (93) · Spain (85) · Canada (81) · United Kingdom (75) · Belgium (71) · Australia (69) · Austria (57) · Czechia (57) · South Korea (55) · Poland (53) · Netherlands (50)
Qifa Liu (5) · Alan K. Burnett, MD, FRCP (3) · Depei Wu, M.D., Ph.D. (3) · Mary Horowitz, MD, MS (3) · Ruediger Hehlmann, MD (3) · Alan S. Gamis, MD, MPH (2) · Brenda Sandmaier (2) · Franco Mandelli, MD (2)
PMID 37267439, PMID 37341189, PMID 22965967, PMID 31375516, PMID 36184192, PMID 36815378, PMID 38295280, PMID 42085603, PMID 19602710, PMID 20625116, PMID 21343560, PMID 21459791, PMID 22649106, PMID 23248249, PMID 23515925, PMID 23620574, PMID 23749683, PMID 23841729, PMID 24816240, PMID 24859364, PMID 25987659, PMID 28273028, PMID 29859851, PMID 29926156, PMID 30337300, PMID 30523055, PMID 32499241, PMID 34596937, PMID 35235189, PMID 35829925, PMID 36064577, PMID 37185873, PMID 37553873, PMID 37703506, PMID 40294366, PMID 40973764, PMID 42668697, PMID 10438706, PMID 12424199, PMID 12637609, PMID 15010373, PMID 15459300, PMID 15761020, PMID 16136166, PMID 16333838, PMID 16484584, PMID 16932345, PMID 16939487, PMID 16960978, PMID 16996130
2015 (7), 2025 (7), 2016 (6), 2014 (5), 2023 (5), U10CA021115 (5), 2017 (4), 2018 (4), U10CA031946 (4), U10CA032102 (4), U10CA098543 (4), U10CA180886 (4), 2008 (3), U01HL069294 (3), U24CA076518 (3)